60 results
ARS
2023 FY
MYGN
Myriad Genetics, Inc.
17 Apr 24
Annual report to shareholders
4:33pm
disease risk or reduce risk of cancer recurrence. The MyRisk Genetic Test Result and MyRisk Management Tool® summarize medical society guidelines
8-K
EX-99.1
MYGN
Myriad Genetics, Inc.
27 Feb 24
Results of Operations and Financial Condition
4:05pm
, as President & Chief Clinical Officer of Oncology, effective March 18, 2024.
In January 2024, the American Society of Clinical Oncology (ASCO)—Society
ARS
2022 FY
MYGN
Myriad Genetics, Inc.
12 Apr 23
Annual report to shareholders
4:10pm
Management Tool® summarize medical society guidelines for managing a patient with a genetic mutation in view of their personal and family history of cancer
8-K
EX-99.1
7l6kelf
4 Aug 22
Myriad Genetics Reports Second Quarter Financial Results
7:06am
8-K
EX-99.1
y8bn10rc
11 Jan 22
Results of Operations and Financial Condition
4:16pm
8-K
EX-99.1
2ca58av80 b647
3 May 21
Myriad Genetics Delivers 12% Sequential Revenue Growth in March 2021 Quarter, Company Executes on Strategic Transformation Initiatives
4:05pm
10-KT
tl17onr5lcdc45kl6k
16 Mar 21
Annual report (with FYE transition)
2:24pm
8-K
EX-99.1
mnc6qfi1cu wwdsgfngb
13 Aug 19
Myriad Genetics Reports Fiscal Fourth-Quarter and Full-Year 2019 Financial Results
4:11pm
8-K
EX-99.1
c08f826cus ki0vsvylh
7 May 19
Myriad Genetics Reports Fiscal Third-Quarter 2019 Financial Results
5:09pm
8-K
EX-99.1
8z46n78
14 Mar 19
Myriad’s myPath® Melanoma Test Receives Medicare Coverage
8:52am